What are the blood loss–related side effects of Eliquis (apixaban)?

Blood Loss-Related Side Effects of Eliquis (Apixaban)

Eliquis (apixaban) causes bleeding as its primary side effect, with rates varying by indication: major bleeding occurs in 0.6-2.1% of patients, clinically relevant non-major bleeding in 3.0-4.2%, and minor bleeding in 8.9-12.1% of patients during treatment. 1

Major Bleeding Events

The FDA label identifies the following major bleeding manifestations with Eliquis:

• Intracranial hemorrhage - significantly lower than warfarin (0.24% vs 0.47% annually in atrial fibrillation patients) 2, 3
• Gastrointestinal bleeding - rates similar to warfarin in atrial fibrillation studies 3
• Fatal bleeding - rare but documented in post-surgical patients 1
• Bleeding requiring transfusion - necessitating ≥2 units of red blood cells in 0.33-0.60% of patients 1
• Bleeding with hemoglobin decrease ≥2 g/dL - occurring in 0.49-0.63% of patients 1

Common Bleeding Side Effects (≥1% incidence)

The FDA label documents these frequent bleeding manifestations: 1

• Epistaxis (nosebleeds) - 1.5-3.6% of patients
• Contusion (bruising) - 1.8-2.2% of patients
• Hematuria (blood in urine) - 1.4-2.1% of patients
• Gingival bleeding (bleeding gums) - 1.0-1.4% of patients
• Hematoma - 1.3-2.0% of patients
• Menorrhagia (heavy menstrual bleeding) - 1.4% of patients
• Rectal hemorrhage - 1.0-1.5% of patients
• Hemoptysis (coughing blood) - 1.2% of patients

Less Common Bleeding Manifestations (0.1-1% incidence)

Additional bleeding sites documented in the FDA label include: 1

• Hemorrhoidal, gastrointestinal, and anal hemorrhage
• Wound hemorrhage and postprocedural bleeding
• Conjunctival, retinal, and ocular hemorrhage
• Vaginal hemorrhage and metrorrhagia
• Muscle hemorrhage
• Skin hemorrhage, ecchymosis, and petechiae

Factors Increasing Bleeding Risk

Critical risk factors that increase bleeding with Eliquis include: 4, 1

• Concurrent antiplatelet therapy (aspirin, clopidogrel) - substantially increases bleeding risk
• History of bleeding - even minor bleeding history predicts future events 4
• Advanced age (≥75-80 years) - associated with higher bleeding rates 4
• Renal impairment - particularly with creatinine clearance <30 mL/min 5, 6
• Low body weight (<60 kg) - increases drug exposure 3
• Concurrent NSAIDs or SSRIs/SNRIs - potentiate bleeding risk 1

Comparative Bleeding Risk

Recent high-quality evidence demonstrates apixaban has lower bleeding risk compared to other anticoagulants:

• Versus rivaroxaban for VTE: Apixaban showed significantly lower clinically relevant bleeding (3.3% vs 7.1%; relative risk 0.46,95% CI 0.33-0.65, P<0.001) in a 2026 randomized trial 7
• Versus warfarin: Major bleeding reduced by 69% (2.13% vs 3.09% annually; HR 0.69,95% CI 0.60-0.80) 2, 3
• Versus enoxaparin/warfarin for VTE: Major bleeding reduced by 69% (0.6% vs 1.8%; relative risk 0.31,95% CI 0.17-0.55, P<0.0001) 1

Special Population Considerations

Severe chronic kidney disease (CKD stage 4/5): The 5 mg dose was associated with higher bleeding risk compared to 2.5 mg (4.9 vs 2.9 events per 100 person-years) without additional efficacy benefit, supporting dose reduction in this population 6

Acute kidney injury: Apixaban use during AKI resulted in 7.8% major bleeding rate (higher than typical), though not statistically different from non-AKI patients (3.4%, P=0.15), warranting cautious use 8

Cancer patients: Reduced-dose apixaban (2.5 mg twice daily) for extended VTE treatment showed lower composite bleeding/thrombosis risk (relative risk 0.77,95% CI 0.64-0.93) compared to full-dose in a 2026 meta-analysis 9

Critical Safety Warnings

The FDA black box warning emphasizes: 1

• Abrupt discontinuation increases stroke risk - particularly in atrial fibrillation patients; bridging anticoagulation should be considered when stopping
• Spinal/epidural hematoma risk - with neuraxial anesthesia or spinal puncture, potentially causing permanent paralysis
• Life-threatening bleeding - can occur and may lead to death; requires immediate medical attention

Management of Bleeding

For life-threatening or uncontrolled bleeding: 10, 11

• First-line interventions should be attempted before reversal agents (local hemostatic measures, nasal packing for epistaxis)
• Andexanet alfa is the specific reversal agent for apixaban (Class IIa recommendation) 11
• 4-factor prothrombin complex concentrate (PCC) is an alternative if andexanet alfa unavailable 10, 11
• Avoid routine reversal for non-life-threatening bleeding to prevent thrombotic complications 10

Clinical Monitoring Recommendations

Routine laboratory monitoring of apixaban levels is not required, but should be considered in: 12

• Suspected overdose or major bleeding
• Before urgent surgery/invasive procedures
• Extremes of body weight (<60 kg or >120 kg)
• Severe renal impairment (CrCl 15-29 mL/min)
• Concern for drug-drug interactions